SPIA
NBIX icon

Steward Partners Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Steward Partners Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
684
+426
+165% +$63.2K ﹤0.01% 2515
2026
Q1 		$34K Buy
258
+216
+514% +$28.7K ﹤0.01% 2977
2025
Q4 		$5.96K Buy
42
+24
+133% +$3.48K ﹤0.01% 3637
2025
Q3 		$2.53K Buy
18
+9
+100% +$1.22K ﹤0.01% 3861
2025
Q2 		$1.13K Sell
9
-12
-57% -$1.38K ﹤0.01% 3839
2025
Q1 		$2.32K Hold
21
– – ﹤0.01% 3610
2024
Q4 		$2.87K Sell
21
-100
-83% -$12.4K ﹤0.01% 3539
2024
Q3 		$13.9K Buy
121
+21
+21% +$2.88K ﹤0.01% 2815
2024
Q2 		$13.8K Sell
100
-459
-82% -$62.9K ﹤0.01% 2673
2024
Q1 		$77.1K Buy
559
+459
+459% +$62.7K ﹤0.01% 1887
2023
Q4 		$13.2K Hold
100
– – ﹤0.01% 2584
2023
Q3 		$11.3K Hold
100
– – ﹤0.01% 2550
2023
Q2 		$9.43K Hold
100
– – ﹤0.01% 2588
2023
Q1 		$10.1K Hold
100
– – ﹤0.01% 2534
2022
Q4 		$11.9K Hold
100
– – ﹤0.01% 2474
2022
Q3 		$11K Buy
+100
New +$10.1K ﹤0.01% 2492
2020
Q4 		– Sell
-36
Closed -$3K – 2959
2020
Q3 		$3K Buy
+36
New +$4.16K ﹤0.01% 2509
2020
Q1 		– Sell
-100
Closed -$10K – 2626
2019
Q4 		$10K Hold
100
– – ﹤0.01% 2018
2019
Q3 		$9K Hold
100
– – ﹤0.01% 2050
2019
Q2 		$8K Buy
+100
New +$8.21K ﹤0.01% 2079
2018
Q4 		– Sell
-1,029
Closed -$127K – 1638
2018
Q3 		$127K Buy
+1,029
New +$117K 0.01% 857

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steward Partners Investment Advisory's NBIX Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its Neurocrine Biosciences (NBIX) stake by 165% in Q2 2026, buying an estimated $63.2K and bringing the position to 684 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #2515.

Steward Partners Investment Advisory first reported a position in NBIX in Q3 2018 and has held it in 21 quarters since. The position peaked at $127K in Q3 2018. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Steward Partners Investment Advisory held 684 shares of Neurocrine Biosciences worth $115K as of Q2 2026.
  • Steward Partners Investment Advisory bought 426 Neurocrine Biosciences shares in Q2 2026, an estimated $63.2K.
  • Neurocrine Biosciences made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2515 holding.
  • Steward Partners Investment Advisory first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 21 quarters since.
  • Steward Partners Investment Advisory's Neurocrine Biosciences position peaked at $127K in Q3 2018.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.